Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Optimi Health Corp., a Vancouver-based pharmaceutical company specializing in the production and distribution of psychedelic drug products, has announced the pricing of its underwritten public offering, aiming to raise approximately $15 million. The offering, which consists of 2,400,000 common shares priced at $6.25 each, is set to close on or about May 21, 2026. The shares will begin trading on the Nasdaq Capital Market under the ticker symbol "OPTH," marking a significant milestone for the company as it uplists from the Canadian Securities Exchange.

The decision to pursue this public offering comes as Optimi Health seeks to capitalize on the growing interest and investment in the psychedelic pharmaceuticals sector. This market has gained traction due to increasing research into the therapeutic benefits of psychedelics for various mental health conditions, including depression and PTSD. The funds raised from this offering are intended to enhance the company’s production capabilities, support market expansion efforts—particularly into the U.S.—and address general working capital needs.

Joseph Gunnar & Co., LLC is acting as the sole book-running manager for the offering, which also includes an option for the underwriter to purchase an additional 360,000 shares. This flexibility may provide additional capital should demand exceed expectations. The offering is being conducted under a registration statement filed with the U.S. Securities and Exchange Commission, which was declared effective shortly before the announcement, ensuring compliance with regulatory requirements.

Optimi Health's strategic focus on psychedelics aligns with broader sector dynamics that indicate a shift in public perception and regulatory approaches to these substances. As more jurisdictions explore decriminalization and therapeutic applications, companies like Optimi are well-positioned to leverage their expertise and product offerings in a rapidly evolving landscape. The anticipated uplisting to Nasdaq is expected to enhance visibility and attract institutional investors, further solidifying the company’s market presence.

In conclusion, the successful completion of this offering may serve as a bellwether for the psychedelic pharmaceuticals sector, reflecting growing investor confidence and interest. As Optimi Health embarks on this new chapter, its ability to scale operations and effectively navigate the complexities of the U.S. market will be critical. The broader implications of this offering could signal a trend toward increased capital flows into the psychedelic space, as companies seek to innovate and expand their therapeutic portfolios in response to rising demand.